Success Stories: Healing Through Precision: A Dual Triumph in Oncology
Client’s Testimonial:
On June 11th, 2025, and June 12th, 2025, we received another EB-2 NIW (National Interest Waiver) and EB-1A (Alien of Extraordinary Ability) approvals for an Attending Doctor in the Field of Oncology (Approval Notice).
General Field: Oncology
Position at the Time of Case Filing: Attending Doctor
Country of Origin: China
Country of Residence at the Time of Filing: China
Approval Notice Date: June 11th, 2025 (NIW) and June 12th, 2025 (EB1A)
Processing Time: 5 months, 19 days (NIW) (Premium Processing Requested); 2 months, 25 days (EB1A) (Premium Processing Requested)
Case Summary:
In a story that intertwines medical dedication with policy advocacy, one attending oncologist from China secured both EB‑2 NIW and EB‑1A approvals, backed by insightful strategy and domain-defining research. This extraordinary dual win underscores the profound impact of his work in oncology, from the clinical trench to national benefit.
1 | Breaking Ground with Cancer Care
Now working as an attending doctor, the client specializes in personalized oncology, developing tailored treatment regimens grounded in molecular diagnostics and tumor genomics. His research aims to refine patient stratification, enabling more effective and less toxic therapies.
2 | Standing on the Shoulders of Scholarship
● Publications: The client has authored 27 peer-reviewed papers, combining clinical research with translational studies.
● Citations: These works have garnered 542 citations, including multiple papers ranking in the top 5% of oncology research.
● Peer Review: Actively contributes as a reviewer for 9 high-impact oncology journals, reinforcing his standing in the academic community.
3 | Fueling Discovery with Funding
The client’s work earned backing from competitive sources, including grants from NIH-affiliated foundations and cancer research trusts, affirming the importance of his contributions to advancing U.S. cancer research and patient care.
4 | Voices That Echo His Impact
One LOR excerpt captures both scientific and societal resonance:
“His integrative biomarker framework has streamlined treatment decisions for metastatic disease, offering hope where none existed and reducing time-to-treatment variability.”
This comment powerfully illustrates how the client’s work is saving lives and improving the consistency of oncology care.
5 | From RFE to Approval: A Strategic Path Forward
Both petitions faced Requests for Evidence on February 11, 2025 (NIW) and April 30, 2025 (EB‑1A). But armed with quantitative metrics, expert letters, and a cohesive presentation of his national and international influence, both petitions were approved swiftly:
● EB‑2 NIW approved on June 11, 2025
● EB‑1A approved on June 12, 2025
Our legal strategy highlighted:
● The national importance of accelerating precision oncology
● The client’s qualification to advance treatment for U.S. patients
● Concrete evidence of his extraordinary ability via citation benchmarks, funding history, peer review roles, and expert endorsement
6 | A New Chapter in Cancer Care Excellence
In less than seven months, this oncologist earned dual approvals and overcame procedural hurdles, bringing new hope to U.S. cancer patients. His NIH-funded research, authoritative reviews, and respected LORs have positioned him not just as a practitioner but as a national asset in precision oncology.
NAILG is honored to have supported this physician-scientist in transforming challenges into a pathway for U.S. innovation and patient care.
This narrative emphasizes both the strategic and human dimensions of the case, demonstrating how scientific leadership and clinical excellence can align with national priorities.